ADMA Biologics Inc (NASDAQ:ADMA) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• ADMA Biologics has a consensus “Hold” rating from six analysts: three recommend buying, two advise holding, and one recommends selling. The average 12-month price target is $18.67.
• Recent analyst actions were mixed, with Mizuho and Canaccord Genuity cutting their price targets, while Raymond James initiated coverage with an “Outperform” rating and a $21 target.
• ADMA reported quarterly EPS of $0.16, in line with estimates, while revenue of $124.39 million fell slightly short of expectations but increased 2% year over year. Institutional investors own approximately 75.68% of the company.

ADMA Biologics Inc (NASDAQ:ADMA - Get Free Report) has been assigned a consensus recommendation of "Hold" from the six brokerages that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $18.6667.

Several equities analysts recently issued reports on the company. Weiss Ratings reaffirmed a "hold (c)" rating on shares of ADMA Biologics in a report on Thursday, June 18th. Wall Street Zen lowered ADMA Biologics from a "buy" rating to a "hold" rating in a report on Monday, May 4th. Mizuho dropped their price target on ADMA Biologics from $20.00 to $17.00 and set an "outperform" rating for the company in a research report on Wednesday, July 15th. Raymond James Financial assumed coverage on ADMA Biologics in a research note on Wednesday, June 10th. They set an "outperform" rating and a $21.00 price target for the company. Finally, Canaccord Genuity Group decreased their price objective on shares of ADMA Biologics from $21.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday, May 7th.

Hedge Funds Weigh In On ADMA Biologics

A number of institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in ADMA Biologics during the second quarter worth approximately $321,037,000. Janus Henderson Group PLC raised its holdings in ADMA Biologics by 3,906.1% in the 4th quarter. Janus Henderson Group PLC now owns 3,936,419 shares of the biotechnology company's stock valued at $71,820,000 after acquiring an additional 3,838,158 shares during the last quarter. Capital Research Global Investors raised its holdings in ADMA Biologics by 104.0% in the 4th quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company's stock valued at $121,067,000 after acquiring an additional 3,383,559 shares during the last quarter. Caligan Partners LP purchased a new position in shares of ADMA Biologics during the 3rd quarter worth $38,653,000. Finally, UBS Group AG lifted its stake in shares of ADMA Biologics by 129.9% during the 4th quarter. UBS Group AG now owns 4,569,343 shares of the biotechnology company's stock worth $83,345,000 after purchasing an additional 2,581,670 shares during the period. Institutional investors and hedge funds own 75.68% of the company's stock.

ADMA Biologics Price Performance

ADMA stock opened at $9.47 on Friday. The firm has a 50 day moving average of $8.81 and a 200-day moving average of $11.04. ADMA Biologics has a 12-month low of $7.21 and a 12-month high of $20.46. The company has a current ratio of 6.97, a quick ratio of 3.81 and a debt-to-equity ratio of 0.49. The company has a market cap of $2.12 billion, a price-to-earnings ratio of 13.53 and a beta of 0.74.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 EPS for the quarter, hitting the consensus estimate of $0.16. The business had revenue of $124.39 million for the quarter, compared to analyst estimates of $125.34 million. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%.The company's quarterly revenue was up 2.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.14 EPS. As a group, equities analysts expect that ADMA Biologics will post 0.78 EPS for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source